Pfizer Licenses AI Platform from Chai Discovery to Accelerate Drug Discovery
Reported by Reuters
Sentiment
Positive
Importance
7
Price
$25.755
Mkt Cap
$146.789B
52W Low
$23.08
52W High
$28.745
Market data snapshot near publication time
Summary
Pfizer has entered a license agreement with Chai Discovery, allowing its scientists to leverage Chai Discovery's AI platform. This strategic partnership aims to accelerate drug discovery research. The move signals Pfizer's commitment to integrating advanced technology to enhance its R&D pipeline and improve efficiency in developing new treatments.
At the time of this announcement, PFE was trading at $25.76 on NYSE in the Life Sciences sector, with a market capitalization of approximately $146.8B. The 52-week trading range was $23.08 to $28.75. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.
Price Chart
PFE - Latest Insights
PFE
Jun 05, 2026, 3:13 AM EDT
PFE
Jun 04, 2026, 10:51 AM EDT
PFE
May 30, 2026, 8:06 AM EDT
PFE
May 30, 2026, 3:13 AM EDT
PFE
May 29, 2026, 8:11 AM EDT
PFE
May 28, 2026, 7:00 PM EDT
PFE
May 20, 2026, 5:05 AM EDT
PFE
May 13, 2026, 6:46 AM EDT
PFE
May 05, 2026, 7:03 AM EDT
PFE
May 05, 2026, 7:01 AM EDT